ATE209902T1 - Neue liposomkomplexe mit erhöhter systemischer verabreichung - Google Patents
Neue liposomkomplexe mit erhöhter systemischer verabreichungInfo
- Publication number
- ATE209902T1 ATE209902T1 AT97938096T AT97938096T ATE209902T1 AT E209902 T1 ATE209902 T1 AT E209902T1 AT 97938096 T AT97938096 T AT 97938096T AT 97938096 T AT97938096 T AT 97938096T AT E209902 T1 ATE209902 T1 AT E209902T1
- Authority
- AT
- Austria
- Prior art keywords
- liposomes
- expression
- highly efficient
- liposome complexes
- systemic administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2438696P | 1996-08-19 | 1996-08-19 | |
| PCT/US1997/013599 WO1998007408A1 (en) | 1996-08-19 | 1997-08-01 | Novel liposome complexes for increased systemic delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE209902T1 true ATE209902T1 (de) | 2001-12-15 |
Family
ID=21820321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97938096T ATE209902T1 (de) | 1996-08-19 | 1997-08-01 | Neue liposomkomplexe mit erhöhter systemischer verabreichung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6413544B1 (de) |
| EP (1) | EP0955999B1 (de) |
| JP (1) | JP4203835B2 (de) |
| AT (1) | ATE209902T1 (de) |
| AU (1) | AU730771B2 (de) |
| CA (1) | CA2263705C (de) |
| DE (1) | DE69708919T2 (de) |
| WO (1) | WO1998007408A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288266B2 (en) * | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| AUPQ002399A0 (en) * | 1999-04-28 | 1999-05-20 | Australian National University, The | Model membrane systems |
| EP1754488A1 (de) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten |
| WO2000071096A2 (en) * | 1999-05-24 | 2000-11-30 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| TR199901199A3 (tr) * | 1999-05-31 | 2001-09-21 | Kocagoez Tanil | Bakteri transformasyon kiti |
| AUPQ259399A0 (en) | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
| US10293056B1 (en) * | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| US6477426B1 (en) * | 2000-06-20 | 2002-11-05 | Celsion Corporation | System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| US20040082521A1 (en) * | 2002-03-29 | 2004-04-29 | Azaya Therapeutics Inc. | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| US20060003316A1 (en) * | 2002-07-15 | 2006-01-05 | John Simard | Immunogenic compositions derived from poxviruses and methods of using same |
| US20040048260A1 (en) * | 2002-09-10 | 2004-03-11 | Fu-Hsiung Chang | Transfection of nucleic acid |
| US7179484B2 (en) * | 2002-11-06 | 2007-02-20 | Azaya Therapeutics, Inc. | Protein-stabilized liposomal formulations of pharmaceutical agents |
| WO2004104032A2 (en) | 2003-05-14 | 2004-12-02 | The University Of Iowa Research Foundation | Methods and compositions related to high-titer pseudotyped retroviruses |
| US8034790B2 (en) | 2003-12-01 | 2011-10-11 | Introgen Therapeutics | Use of MDA-7 to inhibit pathogenic infectious organisms |
| WO2005092288A1 (en) | 2004-03-19 | 2005-10-06 | Let There Be Hope Medical Research Institute | Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds |
| RU2007138027A (ru) | 2005-03-14 | 2009-04-20 | Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) | Биоактивные пептиды fus-1 и комплексы полипептидов с наночастицами |
| EP1867726A4 (de) * | 2005-03-24 | 2008-09-24 | Univ Hokkaido Nat Univ Corp | Zur wirksamen zuführung einer gegebenen substanz in den zellkern fähiges liposom |
| WO2007041206A2 (en) | 2005-09-30 | 2007-04-12 | Auburn University | Drug delivery nanocarriers targeted by landscape phage |
| EP2441770A1 (de) | 2006-02-10 | 2012-04-18 | The University of Cincinnati | Phosphatasehemmer-Protein 1 als Regulator der Herzfunktion |
| CA2649182C (en) | 2006-04-07 | 2018-01-02 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
| NZ578541A (en) | 2006-12-22 | 2012-04-27 | Soluciones Biotecnologicas Innovacion Ltda | Dna vaccines for fish |
| EP2117304A4 (de) * | 2007-02-07 | 2011-08-24 | Gradalis Inc | Verfahren und zusammensetzung zur modulation einer sialsäureproduktion und zur behandlung vererbter einschlusskörper-myopathie |
| WO2009049089A1 (en) * | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
| CN101868180A (zh) | 2007-10-09 | 2010-10-20 | 圣路易斯华盛顿州立大学 | 成像粒子 |
| WO2009094647A2 (en) | 2008-01-25 | 2009-07-30 | Introgen Therapeutics, Inc. | P53 biomarkers |
| US8563690B2 (en) * | 2008-11-03 | 2013-10-22 | The Board Of Trustees Of The University Of Illinois | Modulation of platelet aggregation |
| US9409983B2 (en) | 2009-07-23 | 2016-08-09 | The Board Of Trustess Of The University Of Illinois | Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases |
| EP2512452B1 (de) | 2009-12-17 | 2018-09-19 | The Washington University | Antithrombotisches nanopartikel |
| US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
| JP2013527157A (ja) | 2010-04-15 | 2013-06-27 | ワシントン・ユニバーシティ | プロドラッグ組成物、プロドラッグナノ粒子およびその使用方法 |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
| EP2741784B1 (de) | 2011-03-02 | 2017-05-17 | Board Of Regents, The University Of Texas System | Tusc2 therapien |
| US10040853B2 (en) | 2011-09-09 | 2018-08-07 | Fred Hutchinson Cancer Research Center | Methods and compositions involving NKG2D inhibitors and cancer |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| CN105940110A (zh) | 2014-01-31 | 2016-09-14 | 菲克特生物科学股份有限公司 | 用于核酸产生和递送的方法和产品 |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| TWI725008B (zh) * | 2015-01-28 | 2021-04-21 | 瑞采生技有限公司 | 用於增強ＰＰＡＲγ表現及核轉位之化合物及其醫療用途 |
| WO2016131052A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| EP3349730B1 (de) * | 2015-09-18 | 2020-12-02 | Dnarx | Systeme zur in-vivo-nukleinsäureexpression |
| WO2017079202A1 (en) | 2015-11-02 | 2017-05-11 | Board Of Regents, The University Of Texas System | Methods of cd40 activation and immune checkpoint blockade |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| WO2017216775A2 (en) | 2016-06-16 | 2017-12-21 | The Regents Of The University Of California | Identification of factor that promotes human hsc self-renewal |
| JP7099967B2 (ja) | 2016-07-01 | 2022-07-12 | リサーチ ディベロップメント ファウンデーション | 幹細胞由来移植片からの増殖性細胞の排除 |
| IL308824A (en) | 2016-08-17 | 2024-01-01 | Factor Bioscience Inc | Nucleic acid products and methods of administration thereof |
| CA3040458A1 (en) | 2016-10-12 | 2018-04-19 | Board Of Regents, The University Of Texas System | Methods and compositions for tusc2 immunotherapy |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| CN116392609A (zh) | 2017-03-23 | 2023-07-07 | Dnarx公司 | 用于体内核酸表达的系统和方法 |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| US10945955B2 (en) * | 2018-04-25 | 2021-03-16 | University Of Massachusetts | Artificial exosome composition and related methods |
| EP3790533A1 (de) * | 2018-05-08 | 2021-03-17 | University of Florida Research Foundation, Incorporated | Magnetische liposomen und zugehörige behandlungs- und abbildungsverfahren |
| CN108653750B (zh) * | 2018-06-01 | 2022-04-22 | 成都诺恩基因科技有限公司 | 包裹质粒dna的阳离子脂质体复合物 |
| ES2975662T3 (es) | 2018-10-31 | 2024-07-11 | Univ Arizona | Biomarcadores y métodos de uso para la lesión pulmonar inducida por radiación |
| JP7765379B2 (ja) | 2019-08-12 | 2025-11-06 | ピュリノミア バイオテック， インコーポレイテッド | Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物 |
| TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
| EP4412711A1 (de) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Serumhalbwertszeiterweiterte pd-l1-bindende polypeptide |
| WO2023153876A1 (ko) | 2022-02-10 | 2023-08-17 | 주식회사 아피셀테라퓨틱스 | Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도 |
| WO2023212483A1 (en) | 2022-04-29 | 2023-11-02 | Purinomia Biotech, Inc. | Methods and compositions for treating eosinophil driven diseases and disorders |
| WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5206027A (en) * | 1990-09-13 | 1993-04-27 | Fuji Photo Film Co., Ltd. | Amphipathic compound and liposome comprising the same |
| WO1993024640A2 (en) * | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
-
1997
- 1997-08-01 CA CA002263705A patent/CA2263705C/en not_active Expired - Lifetime
- 1997-08-01 US US09/242,190 patent/US6413544B1/en not_active Expired - Lifetime
- 1997-08-01 AT AT97938096T patent/ATE209902T1/de not_active IP Right Cessation
- 1997-08-01 WO PCT/US1997/013599 patent/WO1998007408A1/en not_active Ceased
- 1997-08-01 JP JP51076598A patent/JP4203835B2/ja not_active Expired - Lifetime
- 1997-08-01 AU AU40502/97A patent/AU730771B2/en not_active Expired
- 1997-08-01 DE DE69708919T patent/DE69708919T2/de not_active Expired - Lifetime
- 1997-08-01 EP EP97938096A patent/EP0955999B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2263705C (en) | 2007-12-04 |
| AU4050297A (en) | 1998-03-06 |
| DE69708919T2 (de) | 2002-06-27 |
| JP2000516630A (ja) | 2000-12-12 |
| EP0955999A1 (de) | 1999-11-17 |
| WO1998007408A1 (en) | 1998-02-26 |
| DE69708919D1 (de) | 2002-01-17 |
| CA2263705A1 (en) | 1998-02-26 |
| US20020028219A1 (en) | 2002-03-07 |
| US6413544B1 (en) | 2002-07-02 |
| EP0955999B1 (de) | 2001-12-05 |
| AU730771B2 (en) | 2001-03-15 |
| JP4203835B2 (ja) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69708919D1 (de) | Neue liposomkomplexe mit erhöhter systemischer verabreichung | |
| Kawakami et al. | Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes | |
| CA2270396A1 (en) | Cationic reagents for transfection | |
| DE69906977D1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
| EP0759694A4 (de) | Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen | |
| ATE362991T1 (de) | Kondensierte plasmid-liposome komplex zur transfektion | |
| Loughrey et al. | A non-covalent method of attaching antibodies to liposomes | |
| EP0743958A4 (de) | Nicht-viraler vektor | |
| IL130823A0 (en) | Peptide-lipid conjugates liposomes and liposomal drug delivery | |
| ATE273320T1 (de) | Fusogene liposomen | |
| WO1997011682A3 (en) | Emulsion and micellar formulations for the delivery of biologically active substances to cells | |
| WO1997030024A3 (de) | Lipidverbindungen und deren verwendung z.b. in liposomen | |
| DK0774959T3 (da) | Liposomalt indgivelsessystem for biologisk aktive midler | |
| ATE322255T1 (de) | Polyamid-oligomere | |
| CA2219119A1 (en) | Nucleic acid ligand complexes | |
| DE69841536D1 (de) | Zielgerichtete Liposomen zur Verabreichung von Genen | |
| EP0769968A4 (de) | Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden | |
| AU4089899A (en) | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy | |
| ATE419833T1 (de) | Modulares zielgerichtetes liposomales verabreichungssytem | |
| EE200000102A (et) | Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene | |
| WO1999065461A3 (en) | Cationic amphiphile micellar complexes | |
| AU6468199A (en) | Method to treat haemophilia by (in vivo) gene therapy with retroviral vectors | |
| ATE359764T1 (de) | Durch liposome vermittelte dna verabreichung | |
| MX9708111A (es) | Lipidos cationicos para terapia genica. | |
| TR199701225A2 (xx) | Gen terapisi için katyonik lipidler. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |